HippoFi and its subsidiary PUR Biologics have FDA 510(k) clearance for ActiveOrb technology and a global license from Zimmer Biomet to use in the spine market, according to a Sept. 7 news release. The companies are working under a joint commercialization research agreement to produce spine-specific products.
The synthetic biomaterial is expected to launch in 2024.
